Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyond Air Inc XAIR

Healthcare Medical Devices
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through... see more

Recent & Breaking News (NDAQ:XAIR)

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference

GlobeNewswire June 27, 2018

AIT Therapeutics Reports Positive Top Line Results from its Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study in Infants

GlobeNewswire June 13, 2018

AIT Therapeutics Announces Change to Fiscal Year End and Financial Results Conference Call and Webcast for the Three Months Ended March 31, 2018

GlobeNewswire June 7, 2018

AIT Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

GlobeNewswire May 30, 2018

AIT Therapeutics Presented Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex (MABSC) at the 2018 American Thoracic Society Conference  

GlobeNewswire May 23, 2018

AIT Therapeutics to Present Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex at the 2018 American Thoracic Society Conference  

GlobeNewswire May 15, 2018

AIT Therapeutics Names Stephen J. DiPalma as Chief Financial Officer

GlobeNewswire April 16, 2018

AIT Granted New Patent for Its Nitric Oxide (NO) Generator and Delivery System

GlobeNewswire March 29, 2018

AIT Therapeutics Announces Year End 2017 Financial Results Conference Call and Webcast

GlobeNewswire March 13, 2018

AIT Therapeutics to Present at Two Investor Conferences

GlobeNewswire March 7, 2018

AIT Therapeutics Appoints Two Senior Executives in Research and Clinical Operations

GlobeNewswire February 20, 2018

AIT Therapeutics Announces $9.82 Million Private Placement

GlobeNewswire February 16, 2018

AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System

GlobeNewswire January 31, 2018

AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients

GlobeNewswire January 22, 2018

AIT Therapeutics Appoints Yoori Lee to its Board of Directors

GlobeNewswire January 2, 2018

AIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology Journal

GlobeNewswire December 1, 2017

AIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients

GlobeNewswire November 27, 2017

AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017 at 7:30 a.m.

GlobeNewswire November 21, 2017

AIT Therapeutics Reports Third Quarter 2017 Financial Results

GlobeNewswire November 3, 2017

AIT Therapeutics Completes Treatment of Patient Infected with NTM abscessus at the National Institute of Health (NIH) with its Nitric Oxide (NO) Treatment

GlobeNewswire November 2, 2017